Genetically Modified T Cells Against Ovarian Cancer

The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).

Trial Details

NCT ID
NCT03184753
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Geno-Immune Medical Institute
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • OC-IgT cells
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Written, informed consent obtained prior to any study-specific procedures.
  • Female patients ≥ 20 years.
  • Eastern Cooperative Oncology Group (ECOG) PS of 0, 1 or 2.
  • Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →